SCHEMBL2107203

SCHEMBL2107203

O=C(O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(-n3ccnc3)cc2)CN1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.48
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
HTR2B P41595 1/20 0.44
ADH5 P11766 1/20 0.43
CYP3A4 P08684 3/20 0.42
BAZ2B Q9UIF8 1/20 0.42
ENPP2 Q13822 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
CYP2D6 P10635 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
TBXAS1 P24557 2/20 0.40
HTT P42858 2/20 0.40
ACP1 P24666 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695792 0.81 CTSS (0.53)
Hydrochloric Acid SCHEMBL699026 0.81 CTSS (0.52)
SCHEMBL3065766 0.80 ADH5 (0.42) CHRNA7HTR2AHTR2CHTR2BADH5
SCHEMBL15338534 0.76 CHRNA7 (0.49) CHRNA7HTR2AHTR2CHTR2BCYP3A4
SCHEMBL3080915 0.75 CTSS (0.47) HTR2ACYP2D6ALOX15
SCHEMBL15327298 0.73 CTSS (0.40) CHRNA7HTR2AHTR2CHTR2B
SCHEMBL19604273 0.69 CA2 (0.42) HTR2AHTR2CCYP2D6HTTMEN1
SCHEMBL10423949 0.69 ENPP2 (0.59) CHRNA7HTR2AHTR2CHTR2BADH5
SCHEMBL9594739 0.68 NOTUM (0.61) CHRNA7HTR2AHTR2CHTR2BADH5
SCHEMBL12970841 0.67 ALDH1A1 (0.58) CHRNA7HTR2AHTR2CHTR2BADH5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CHRNA7 4772/4885HTR2A 2196/4885HTR2C 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.